Selected scientific papers
This section contains a selection of Dr. Breggin's scientific articles spanning 1964 to the present. They can be arranged chronologically in order to facilitate an overview of his work over the years.
 
 

DocumentsDate added

Order by : Name | Date | Hits | [ Descendent ]
file icon Risks and Mechanism of Action of Stimulants 11/16/1998
Risks and Mechanism of Action of Stimulants. NIH Consensus Development Conference on Diagnosis and Treatment of Attention Deficit Hyperactivity Disorder, November 16-18, 1998.
file icon Brain damage, dementia and persistent cognitive dysfunction associated with neuroleptics (German) 03/30/1990
"Brain damage, dementia and persistent cognitive dysfunction associated with neuroleptics: Evidence, Etiology, Implications." Journal of Mind Behavior, 11:425-464, 1990. German Edition
file icon A Case of Fluoxetine-induced Stimulant Side Effects with Suicidal Ideation... 01/02/1992
Breggin, P.R. (1992). A Case of Fluoxetine-induced Stimulant Side Effects with Suicidal Ideation Associated with a Possible Withdrawal Syndrome ("Crashing"). International Journal of Risk & Safety in Medicine, 3, 325-328.
file icon Electroshock: Scientific, Ethical, & Political Issues (1998) 01/01/1998
"Electroshock: Scientific, Ethical, and Political Issues." International Journal of Risk & Safety In Medicine, 11:5-40, 1998.
file icon A dangerous assignment (2001) 03/01/2001
"A dangerous assignment," In Howard Rosenthal (Ed.). Favorite Counseling and Therapy Homework Assignments: Leading Therapists Share their Most Creative Strategies, pp. 58-59. Philadelphia: Brunner Routledge, 2001.
file icon From Prozac to Ecstasy: implications of new evidence for drug-induced brain damage (2001) 01/01/2001
"From Prozac to Ecstacy: The Implication of New Evidence for Drug-Induced Brain Damage." Ethical Human Sciences and Services, 3: 3-5, 2001.
file icon Empowering social work in the era of biological psychiatry (2001) 04/01/2001
"Empowering Social Work in the Era of Biological Psychiatry." (2001) [The annual Ephraim Lisansky ecture of the University of Maryland School of Social Work.] Ethical Human Sciences and Services, :197-206.
file icon The FDA should test the safety of ECT machines 07/13/2010
International Journal of Risk & Safety in Medicine 22 (2010) 89-92.
Peter R. Breggin
Abstract: Electroconvulsive therapy (ECT) and the machines that deliver it have never been tested for safety and efficacy in order to receive approval from the FDA. The American Psychiatric Association and ECT advocates protested when the FDA took steps to classify the machines as posing “an unreasonable risk of illness or injury”, which would have required their testing before approval. Without requiring this testing, the FDA is now preparing to classify the treatment and the machines as safe. This article reviews evidence demonstrating that ECT is very harmful to the brain and mind, and concludes that the FDA should demand the usual testing, starting with animals, that is required before psychiatric treatments and machines are approved for marketing and use.
file icon What pyschologists and psychiatrists need to know about ADHD and stimulants 05/01/2000
"What Psychologists and Psychotherapists Need to Know About ADHD and Stimulants." Changes: An International Journal of Psychology and Psychotherapy, 18:13-23, Spring 2000.
file icon Campaigns against racist federal programs by the ICSPP (1995/96) 01/01/1995
"Campaigns against racist federal programs by the Center for the Study of Psychiatry and Psychology." Journal of African American Men 1:No. 3, 3-22. Winter 1995/96.
<< Start < Prev 1 2 3 4 5 6 7 Next > End >>
Results 1 - 10 of 66

 

WARNING!

Most psychiatric drugs can cause withdrawal reactions, sometimes including life-threatening emotional and physical withdrawal problems. In short, it is not only dangerous to start taking psychiatric drugs, it can also be dangerous to stop them. Withdrawal from psychiatric drugs should be done carefully under experienced clinical supervision. Methods for safely withdrawing from psychiatric drugs are discussed in Dr. Breggin's new book, Psychiatric Drug Withdrawal: A Guide for Prescribers, Therapists, Patients, and Their Families.